An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue
Magnetic Resonance Spectroscopy (MRS) allows for the non-invasive quantification of neurochemicals and has the potential to differentiate between the pathologically distinct diseases, multiple sclerosis (MS) and AQP4Ab-positive neuromyelitis optica spectrum disorder (AQP4Ab-NMOSD). In this study we...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2021
|
| _version_ | 1826283262617583616 |
|---|---|
| author | Tackley, G Kong, Y Minne, R Messina, S Winkler, A Cavey, A Everett, R DeLuca, GC Weir, A Craner, M Tracey, I Palace, J Stagg, CJ Emir, U |
| author_facet | Tackley, G Kong, Y Minne, R Messina, S Winkler, A Cavey, A Everett, R DeLuca, GC Weir, A Craner, M Tracey, I Palace, J Stagg, CJ Emir, U |
| author_sort | Tackley, G |
| collection | OXFORD |
| description | Magnetic Resonance Spectroscopy (MRS) allows for the non-invasive quantification of neurochemicals and has the potential to differentiate between the pathologically distinct diseases, multiple sclerosis (MS) and AQP4Ab-positive neuromyelitis optica spectrum disorder (AQP4Ab-NMOSD). In this study we characterised the metabolite profiles of brain lesions in 11 MS and 4 AQP4Ab-NMOSD patients using an optimised MRS methodology at ultra-high field strength (7T) incorporating correction for T2 water relaxation differences between lesioned and normal tissue. MS metabolite results were in keeping with the existing literature: total N-acetylaspartate (NAA) was lower in lesions compared to normal appearing brain white matter (NAWM) with reciprocal findings for myo-Inositol. An unexpected subtlety revealed by our technique was that total NAA differences were likely driven by NAA-glutamate (NAAG), a ubiquitous CNS molecule with functions quite distinct from NAA though commonly quantified together with NAA in MRS studies as total NAA. Surprisingly, AQP4Ab-NMOSD showed no significant differences for total NAA, NAA, NAAG or myo-Inositol between lesion and NAWM sites, nor were there any differences between MS and AQP4Ab-NMOSD for a priori hypotheses. Post-hoc testing revealed a significant correlation between NAWM Ins:NAA and disability (as measured by EDSS) for disease groups combined, driven by the AP4Ab-NMOSD group. Utilising an optimised MRS methodology, our study highlights some under-explored subtleties in MRS profiles, such as the absence of myo-Inositol concentration differences in AQP4Ab-NMOSD brain lesions versus NAWM and the potential influence of NAAG differences between lesions and normal appearing white matter in MS. |
| first_indexed | 2024-03-07T00:56:20Z |
| format | Journal article |
| id | oxford-uuid:8831d3da-b364-4a63-bf6e-c88e879b1e88 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:56:20Z |
| publishDate | 2021 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:8831d3da-b364-4a63-bf6e-c88e879b1e882022-03-26T22:15:37ZAn In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8831d3da-b364-4a63-bf6e-c88e879b1e88EnglishSymplectic ElementsElsevier2021Tackley, GKong, YMinne, RMessina, SWinkler, ACavey, AEverett, RDeLuca, GCWeir, ACraner, MTracey, IPalace, JStagg, CJEmir, UMagnetic Resonance Spectroscopy (MRS) allows for the non-invasive quantification of neurochemicals and has the potential to differentiate between the pathologically distinct diseases, multiple sclerosis (MS) and AQP4Ab-positive neuromyelitis optica spectrum disorder (AQP4Ab-NMOSD). In this study we characterised the metabolite profiles of brain lesions in 11 MS and 4 AQP4Ab-NMOSD patients using an optimised MRS methodology at ultra-high field strength (7T) incorporating correction for T2 water relaxation differences between lesioned and normal tissue. MS metabolite results were in keeping with the existing literature: total N-acetylaspartate (NAA) was lower in lesions compared to normal appearing brain white matter (NAWM) with reciprocal findings for myo-Inositol. An unexpected subtlety revealed by our technique was that total NAA differences were likely driven by NAA-glutamate (NAAG), a ubiquitous CNS molecule with functions quite distinct from NAA though commonly quantified together with NAA in MRS studies as total NAA. Surprisingly, AQP4Ab-NMOSD showed no significant differences for total NAA, NAA, NAAG or myo-Inositol between lesion and NAWM sites, nor were there any differences between MS and AQP4Ab-NMOSD for a priori hypotheses. Post-hoc testing revealed a significant correlation between NAWM Ins:NAA and disability (as measured by EDSS) for disease groups combined, driven by the AP4Ab-NMOSD group. Utilising an optimised MRS methodology, our study highlights some under-explored subtleties in MRS profiles, such as the absence of myo-Inositol concentration differences in AQP4Ab-NMOSD brain lesions versus NAWM and the potential influence of NAAG differences between lesions and normal appearing white matter in MS. |
| spellingShingle | Tackley, G Kong, Y Minne, R Messina, S Winkler, A Cavey, A Everett, R DeLuca, GC Weir, A Craner, M Tracey, I Palace, J Stagg, CJ Emir, U An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue |
| title | An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue
|
| title_full | An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue
|
| title_fullStr | An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue
|
| title_full_unstemmed | An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue
|
| title_short | An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue
|
| title_sort | in vivo 1h mrs short echo time technique at 7t quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue |
| work_keys_str_mv | AT tackleyg aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT kongy aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT minner aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT messinas aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT winklera aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT caveya aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT everettr aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT delucagc aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT weira aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT cranerm aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT traceyi aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT palacej aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT staggcj aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT emiru aninvivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT tackleyg invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT kongy invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT minner invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT messinas invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT winklera invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT caveya invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT everettr invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT delucagc invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT weira invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT cranerm invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT traceyi invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT palacej invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT staggcj invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue AT emiru invivo1hmrsshortechotimetechniqueat7tquantificationofmetabolitesinchronicmultiplesclerosisandneuromyelitisopticabrainlesionsandnormalappearingbraintissue |